title: p120 GAP requirement in normal and malignant human hematopoiesis.
abstract: There is evidence to suggest that the p120 GAP (GAP), originally described as an inhibitor of p21ras, may also serve as a downstream effector of ras-regulated signal transduction. To determine whether GAP expression is required for the growth of human normal and leukemic hematopoietic cells, we used GAP antisense oligodeoxynucleotides to inhibit it and analyzed the effects of this inhibition on the colony-forming ability of nonadherent, T lymphocyte-depleted mononuclear cells and of highly purified progenitors (CD34+ MNC) obtained from the bone marrow and peripheral blood of healthy volunteers or chronic myeloid leukemia (CML, bcr-abl-positive) patients. The acute myelogenous leukemia cell line MO7, the Philadelphia BV173 cell line, and the acute promyelocytic leukemia NB4 and HL-60 cell lines were similarly examined. GAP antisense treatment inhibited colony formation from normal myelo-, erythro-, and megakaryopoietic progenitor cells as well as from CML progenitor cells. Proliferation of MO7 (growth factor-dependent) and BV173 (bcr-abl-dependent) cells, but not that of NB4 and HL-60 (growth factor-independent) cells, was also inhibited, even though a specific downregulation of GAP was observed in each cell line, as analyzed by either or both mRNA and protein expression. Stimulation of MO7 cells with hematopoietic growth factors increased the expression of GAP as well as the levels of active GTP-bound p21ras. Stimulation of GAP expression was inhibited upon GAP antisense treatment. These data indicate that p120 GAP is involved in human normal and leukemic hemopoiesis and strongly suggest that GAP is not only a p21ras inhibitor (signal terminator), but also a positive signal transducer.
authors.affiliation: Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
authors.forename: T
authors.initials: T
authors.lastname: Skorski
authors.forename: P
authors.initials: P
authors.lastname: Kanakaraj
authors.forename: M
authors.initials: M
authors.lastname: Nieborowska-Skorska
authors.forename: M
authors.initials: M
authors.lastname: Ratajczak
authors.forename: C
authors.initials: C
authors.lastname: Szczylik
authors.forename: G
authors.initials: G
authors.lastname: Zon
authors.forename: R B
authors.initials: RB
authors.lastname: Arlinghaus
authors.forename: A
authors.initials: A
authors.lastname: Gewirtz
authors.forename: B
authors.initials: B
authors.lastname: Perussia
authors.forename: B
authors.initials: B
authors.lastname: Calabretta
mesh_terms: D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D016044:Fusion Proteins, bcr-abl / Q000502:physiology; D020690:GTPase-Activating Proteins; D015870:Gene Expression; D006133:Growth Substances / Q000494:pharmacology; D006410:Hematopoiesis; D006801:Humans; D016376:Oligonucleotides, Antisense; D011506:Proteins / Q000502:physiology*; D016283:Proto-Oncogene Proteins p21(ras) / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics; D015398:Signal Transduction; D020703:ras GTPase-Activating Proteins
chemical_list: D020690:GTPase-Activating Proteins; D006133:Growth Substances; D016376:Oligonucleotides, Antisense; D011506:Proteins; D012333:RNA, Messenger; D020703:ras GTPase-Activating Proteins; D016044:Fusion Proteins, bcr-abl; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)